Atossa Therapeutics, Inc. (ATOS)

Piescoffer99 comes here to pump OCGN. Unless their vaccine gets approved in the US they will not make any money on it. They only get paid if it makes money in the US. You already have tow vaccines approved here with two of them much better. He doesn't care about anyone but himself. He tries to lead rookies and those of low IQ into his money losing stock picks!

Even if the pandemic continues for a year or two, other vaccines will likely continue to dominate the market in developed countries while Covaxin could, at best, carve out a very tiny share of this space. And whatever sales it generates will have to be shared with Bharat Biotech. Covaxin's best shot, in my view, is to make waves in countries where vaccines aren't as readily available.

But that wouldn't help Ocugen. And to make matters worse, none of the company's other pipeline programs have even made it to a phase 2 study yet. Any regulatory setback related to Covaxin could send Ocugen's stock spiraling down. Putting all this together, this biotech stock does not look like a particularly attractive investment at the moment. Investors would do better to look elsewhere.

Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce endoxifen and afimoxifene (hydroxytamoxifen).
Astra's Tamoxifen has limitations. When ATOS Endoxifen in market, no one will buy Tamoxifen, that's why Astra is playing 😉
We know how major companies play in markets. Just wait guy...we all will become rich with AtossaTherapeutics 👍